{
    "clinical_study": {
        "@rank": "151498", 
        "acronym": "StatVax", 
        "arm_group": [
            {
                "arm_group_label": "Pneumovax-Atorvastatin", 
                "arm_group_type": "Experimental", 
                "description": "10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7."
            }, 
            {
                "arm_group_label": "Pneumovax-Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research study is to: Improve the effectiveness of vaccinations by\n      identifying the effect of cholesterol medication, statins, on immune responses."
        }, 
        "brief_title": "The Effect of Short-term Atrovastatin Treatment on Immune Responses to Pneumovax 23", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Controls", 
        "detailed_description": {
            "textblock": "Due to the anti-inflammatory action of statins, it was proposed that statin treatment would\n      decrease the efficacy of vaccination.  This response has yet to be explored following a\n      primary vaccination such as pneumococcal pneumonia. In this study, healthy volunteers will\n      be divided into 2 arms receiving treatment for 28 days: 40 mg atorvastatin or placebo.\n\n      Antibody titer for 23 serotypes, complete blood count (CBC), high-sensitivity c-reactive\n      protein (hsCRP), erythrocyte sedimentation rate (ESR), lipids, cytokines (TNF-alpha,\n      IFN-gamma, interleukins, etc.) and key membrane receptors (toll-like receptors, etc.) will\n      be measured for baseline before statin or placebo treatment. On day 7 of treatment,\n      pre-vaccination measures of the above parameters will be taken and an immune response will\n      be induced in all groups using Pneumovax 23 at Day 7. On days 8, 14, 21, and 28\n      post-vaccination measures will be compared to baseline and between groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        24 subjects are healthy volunteers between the ages of 21 and 40.\n\n        Exclusion Criteria:\n\n          1. Pregnant, planning to become pregnant, breastfeeding\n\n          2. Taking any of the following medications at time of study: antacids, antifungals,\n             antioxidants, colestipol, cyclosporine, digoxin, erythromycin, fibric acid\n             derivatives, niacin, oral contraceptives containing norethindrone or ethinyl\n             estradiol, statins, steroids\n\n          3. Taking any immunosuppressive drugs including azathioprine, methotrexate, TNF\n             inhibitors, cyclophosphamide, antimalarials, or sulfasalazine\n\n          4. Currently have or history of cardiovascular disease, diabetes, diphtheria, high blood\n             pressure, high cholesterol, immunodeficiencies, kidney disease, liver disease, low\n             blood pressure, muscular disease, seizure disorders, systemic lupus erythematosus or\n             other systemic autoimmune disorders\n\n          5. Not immunized in childhood against streptococcus pneumoniae; received pneumovax\n             vaccine within past year, or received 2 or more pneumovax boosters within the past 5\n             years\n\n          6. Latex allergy or previous allergic reaction or severe side effects from any vaccine\n\n          7. Heavy drinking (more than 15 drinks/week), illegal drug use within past six months,\n             unwillingness to abstain from alcohol, unwillingness to abstain from tobacco products\n             (dip, cigarettes, cigars, electronic cigarettes, etc.), illegal drugs, or grapefruit\n             juice for duration of study\n\n          8. BMI over 30, abnormal values on lipid panel or liver function test\n\n          9. Failure to pass pre-study medical screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097589", 
            "org_study_id": "IRB201400208"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pneumovax-Atorvastatin", 
                "description": "10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.", 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Lipitor"
            }, 
            {
                "arm_group_label": [
                    "Pneumovax-Atorvastatin", 
                    "Pneumovax-Placebo"
                ], 
                "description": "Pneumovax 23 injected once, intramuscularly at Day 7.", 
                "intervention_name": "Pneumovax 23", 
                "intervention_type": "Drug", 
                "other_name": [
                    "23-valent pneumococcal polysaccharide vaccine", 
                    "PNEUMOVAX 23"
                ]
            }, 
            {
                "arm_group_label": "Pneumovax-Placebo", 
                "description": "10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days.", 
                "intervention_name": "Placebo (lactose pill)", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Health Controls", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "contact": {
                "email": "noltej@ufl.edu", 
                "last_name": "Joanna L Nolte, ARNP", 
                "phone": "352-273-7225"
            }, 
            "facility": {
                "address": {
                    "city": "Gainesville", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32610"
                }, 
                "name": "University of Florida Clinical Translational Research Building"
            }, 
            "investigator": {
                "last_name": "Mark L Brantly, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Short-term Atrovastatin Treatment on Immune Responses to Pneumovax 23", 
        "other_outcome": {
            "description": "The 24 subjects will be randomized into 2 groups of 12 individuals (6 per gender) and will be assigned to receive either atorvastatin treatment (40mg/day) or placebo (lactose pill) control.\nSubjects will be asked to fast after midnight prior to any morning blood draws. On day 1 of treatment, blood will be drawn for a baseline. Treatment with either atorvastatin or placebo will begin on day one and will continue until day 28. Subjects will be instructed to take the study medication once a day at the same time each day.\nOn day seven of treatment, subjects will be immunized with Pneumovax 23, administered intramuscularly into the arm. Blood will be drawn at several time points following Pneumovax 23 administration.  Measurements on blood will be made to determine the effect of statins on immune factor gene expression, serum protein levels, as well as at the cellular level.", 
            "measure": "Determine the effect of atorvastatin treatment on immune-regulatory gene expression.", 
            "safety_issue": "No", 
            "time_frame": "Approximately 49 days"
        }, 
        "overall_contact": {
            "email": "twildes@ufl.edu", 
            "last_name": "Tyler Wildes", 
            "phone": "(904) 536-8704"
        }, 
        "overall_contact_backup": {
            "email": "noltej@ufl.edu", 
            "last_name": "Joanna L Nolte, ARNP", 
            "phone": "3522737225"
        }, 
        "overall_official": {
            "affiliation": "University of Florida", 
            "last_name": "Mark L Brantly, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The 24 subjects will be randomized into 2 groups of 12 individuals (6 per gender) and will be assigned to receive either atorvastatin treatment (40mg/day) or placebo (lactose pill) control.\nSubjects will be asked to fast after midnight prior to any morning blood draws. On day 1 of treatment, blood will be drawn for a baseline. Treatment with either atorvastatin or placebo will begin on day one and will continue until day 28. Subjects will be instructed to take the study medication once a day at the same time each day.\nOn day seven of treatment, subjects will be immunized with Pneumovax 23, administered intramuscularly into the arm. Blood will be drawn at several time points following Pneumovax 23 administration.  Measurements on blood will be made to determine the effect of statins on immune factor gene expression, serum protein levels, as well as at the cellular level.", 
            "measure": "Determine the effect of atorvastatin treatment on pneumococcal antigen specific antibody production.", 
            "safety_issue": "No", 
            "time_frame": "approximately 49 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097589"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The 24 subjects will be randomized into 2 groups of 12 individuals (6 per gender) and will be assigned to receive either atorvastatin treatment (40mg/day) or placebo (lactose pill) control.\nSubjects will be asked to fast after midnight prior to any morning blood draws. On day 1 of treatment, blood will be drawn for a baseline. Treatment with either atorvastatin or placebo will begin on day one and will continue until day 28. Subjects will be instructed to take the study medication once a day at the same time each day.\nOn day seven of treatment, subjects will be immunized with Pneumovax 23, administered intramuscularly into the arm. Blood will be drawn at several time points following Pneumovax 23 administration.  Measurements on blood will be made to determine the effect of statins on immune factor gene expression, serum protein levels, as well as at the cellular level.", 
            "measure": "Determine the effect of atorvastatin treatment on immunogenic cytokine levels following pneumococcal vaccination.", 
            "safety_issue": "No", 
            "time_frame": "approximately 49 days"
        }, 
        "source": "University of Florida", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Florida", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}